Literature DB >> 32953599

Prediction of level V metastases in papillary thyroid microcarcinoma: a single center analysis.

Wenlong Wang1,2, Ning Bai1, Qianhui Ouyang1, Botao Sun1, Chong Shen1, Xinying Li1,2.   

Abstract

BACKGROUND: The rate of level V metastases is significantly low and the necessity of routine level V dissection for papillary thyroid microcarcinoma (PTMC) with clinically lateral lymph node metastasis (LNM) is still controversial.
METHODS: This study enrolled 114 consecutive PTMC patients with clinically suspected lateral LNM (N1b) who underwent modified radical neck dissection (levels II to V) at Xiangya Hospital of Central South University from September 2016 to July 2019. Univariate and multivariate analyses were performed to investigate the predictive factors of level V metastasis. The area under the receiver operating characteristic (ROC) curve (AUC), accuracy, specificity and sensitivity were used to determine the predictive value.
RESULTS: The overall and occult rate of level V metastasis were 29.82% (34/114) and 7.02% (8/114), respectively. Univariate analysis showed that level V metastasis was significantly associated with gross extrathyroidal extension (ETE), level IV metastasis and 2-level simultaneous metastasis (all P<0.05). Gross ETE (OR =11.916, 95% CI, 1.404-102.19; P=0.023) and level IV metastasis (OR =8.497, 95% CI, 2.119-34.065; P =0.03) served as independent predictors of level V metastasis in N1b PTMC patients. The sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) of gross ETE and level IV metastasis in predicting the level V metastasis were 25.3% vs. 82.4%, 97.5% vs. 73.8%, 82.69% vs. 76.32%, 80% vs. 57.04% and 75% vs. 90.77%, respectively. The AUC of gross ETE was lower than level IV metastasis (0.605 vs. 0.781, P=0.041).
CONCLUSIONS: Routine level V dissection is necessary in N1b PTMC patients with level IV metastasis or gross ETE. Compared with gross ETE, level IV metastasis is superior in predicting level V metastasis. 2020 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Papillary thyroid microcarcinoma (PTMC); extrathyroidal extension (ETE); level V

Year:  2020        PMID: 32953599      PMCID: PMC7475379          DOI: 10.21037/gs-20-232

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  27 in total

1.  Thyroid cancer staging and genomics.

Authors:  Ashok R Shaha; R Michael Tuttle
Journal:  Ann Transl Med       Date:  2019-03

2.  Optimal extent of lateral neck dissection for well-differentiated thyroid carcinoma with metastatic lateral neck lymph nodes: A systematic review and meta-analysis.

Authors:  Ho-Ryun Won; Jae Won Chang; Yea Eun Kang; Jae Yoon Kang; Bon Seok Koo
Journal:  Oral Oncol       Date:  2018-11-01       Impact factor: 5.337

Review 3.  The extent of lateral lymph node dissection in differentiated thyroid cancer in the N+ neck.

Authors:  S Kumar; C Burgess; R Moorthy
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-03-22       Impact factor: 2.503

4.  Occult lymph node metastasis and risk of regional recurrence in papillary thyroid cancer after bilateral prophylactic central neck dissection: A multi-institutional study.

Authors:  Young Chan Lee; Se Young Na; Gi Cheol Park; Ju Hyun Han; Seung Woo Kim; Young Gyu Eun
Journal:  Surgery       Date:  2016-08-26       Impact factor: 3.982

5.  Should Level V Be Routinely Dissected in N1b Papillary Thyroid Carcinoma?

Authors:  Seo Ki Kim; Inhye Park; Nayoon Hur; Jun Ho Lee; Jun-Ho Choe; Jung-Han Kim; Jee Soo Kim
Journal:  Thyroid       Date:  2016-11-28       Impact factor: 6.568

6.  Preoperative detection and predictors of level V lymph node metastasis in patients with papillary thyroid carcinoma.

Authors:  M J Shim; J-L Roh; G Gong; K-J Choi; J H Lee; S-H Cho; S Y Nam; S Y Kim
Journal:  Br J Surg       Date:  2012-12-19       Impact factor: 6.939

7.  Is routine dissection of level II-B and V-A necessary in patients with papillary thyroid cancer undergoing lateral neck dissection for FNA-confirmed metastases in other levels.

Authors:  Tarik Farrag; Frank Lin; Noel Brownlee; Matthew Kim; Sheila Sheth; Ralph P Tufano
Journal:  World J Surg       Date:  2009-08       Impact factor: 3.352

8.  Diagnostic Efficiency of Quantitative Contrast-Enhanced Ultrasound Indicators for Discriminating Benign From Malignant Solid Thyroid Nodules.

Authors:  Xiaohui Zhou; Ping Zhou; Zheyu Hu; Shuang Ming Tian; Yongfeng Zhao; Wengang Liu; Qiuzi Jin
Journal:  J Ultrasound Med       Date:  2017-09-07       Impact factor: 2.153

9.  Clinical and Pathologic Predictors of Lymph Node Metastasis and Recurrence in Papillary Thyroid Microcarcinoma.

Authors:  Saaduddin Siddiqui; Michael G White; Tatjana Antic; Raymon H Grogan; Peter Angelos; Edwin L Kaplan; Nicole A Cipriani
Journal:  Thyroid       Date:  2016-05-17       Impact factor: 6.568

10.  Skip metastases to lateral cervical lymph nodes in differentiated thyroid cancer: a systematic review.

Authors:  Andrea Attard; Nunzia Cinzia Paladino; Attilio Ignazio Lo Monte; Nicola Falco; Giuseppina Melfa; Giulia Rotolo; Stefano Rizzuto; Eliana Gulotta; Giuseppe Salamone; Sebastiano Bonventre; Gregorio Scerrino; Gianfranco Cocorullo
Journal:  BMC Surg       Date:  2019-04-24       Impact factor: 2.102

View more
  4 in total

1.  Sex disparities in thyroid cancer: a SEER population study.

Authors:  Peng Li; Ying Ding; Mengyuan Liu; Wenlong Wang; Xinying Li
Journal:  Gland Surg       Date:  2021-12

2.  The influence of nodule size on the aggressiveness of thyroid carcinoma varies with patient's age.

Authors:  Chaoyang Meng; Wenlong Wang; Yuezhong Zhang; Xinying Li
Journal:  Gland Surg       Date:  2021-03

3.  Nomogram individually predicts the risk for distant metastasis and prognosis value in female differentiated thyroid cancer patients: A SEER-based study.

Authors:  Wenlong Wang; Cong Shen; Zhi Yang
Journal:  Front Oncol       Date:  2022-08-10       Impact factor: 5.738

4.  A Potential Four-Gene Signature and Nomogram for Predicting the Overall Survival of Papillary Thyroid Cancer.

Authors:  Ying Ding; Peng Li; Wenlong Wang; Fang Liu
Journal:  Dis Markers       Date:  2022-08-30       Impact factor: 3.464

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.